NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 10/20/2025 at 14:45, 4 months 30 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial

NanoViricides NV-387 Emergency Use Measles Virus Phase I
BRIEF

published on 10/15/2025 at 14:50, 5 months 4 days ago

NanoViricides poursuit une stratégie clinique à double voie pour le NV-387

Antiviral À Large Spectre Essais De Phase II Développement NV-387 Essai MPox Virus Respiratoires
BRIEF

published on 10/15/2025 at 14:50, 5 months 4 days ago

NanoViricides Pursues Dual-Track Clinical Strategy for NV-387

Respiratory Viruses Broad-spectrum Antiviral Phase II Trials NV-387 Development MPox Trial
PRESS RELEASE

published on 10/15/2025 at 14:45, 5 months 4 days ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects

Respiratory Viral Infections NV-387 NanoViricides Inc. Analyst Report Clinical Development Strategy
BRIEF

published on 09/30/2025 at 14:50, 5 months 19 days ago

Progrès du NV-387 de NanoViricides dans les essais cliniques

NanoViricides NV-387 Essais Cliniques Thérapie Antivirale Défis De Financement
BRIEF

published on 09/30/2025 at 14:50, 5 months 19 days ago

NanoViricides' NV-387 Advances in Clinical Trials

NanoViricides NV-387 Clinical Trials Antiviral Therapy Funding Challenges
PRESS RELEASE

published on 09/30/2025 at 14:45, 5 months 19 days ago

NanoViricides, Inc. Has Filed its Annual Report
NanoViricides reports progress on antiviral NV-387 in Phase II clinical trials with potential to revolutionize treatment for respiratory viral infections. Annual report highlights achievements and funding status

NanoViricides NV-387 Clinical Trials Respiratory Infections Antiviral
BRIEF

published on 09/11/2025 at 14:35, 6 months 8 days ago

NanoViricides to Present at LSX World Congress in Boston

NanoViricides NV-387 Clinical Trials Antiviral Drug LSX Congress
BRIEF

published on 09/11/2025 at 14:35, 6 months 8 days ago

NanoViricides sera présenté au congrès mondial LSX à Boston

NanoViricides NV-387 Essais Cliniques Médicament Antiviral Congrès LSX
PRESS RELEASE

published on 09/11/2025 at 14:30, 6 months 8 days ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections

NanoViricides NV-387 Antiviral Drug Viral Infections LSX World Congress

Published on 03/20/2026 at 03:10, 1 hour 35 minutes ago

Future Fuels Announces Filing of Amended and Restated Life Offering Document
Published on 03/20/2026 at 00:20, 4 hours 25 minutes ago

Prospect Ridge To Host Investor Webinar With Presentation And Audience Q&A
Published on 03/20/2026 at 00:20, 4 hours 25 minutes ago

Reeflex Solutions Inc. Announces Revocation of Management Cease Trade Order
Published on 03/19/2026 at 21:16, 7 hours 29 minutes ago

Unusual Machines, Inc. Announces Proposed Public Offering
Published on 03/19/2026 at 14:20, 14 hours 25 minutes ago

CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report

View all ACCESSWIRE

Published on 03/20/2026 at 03:05, 1 hour 39 minutes ago

HEROAD Unleashes a New Era of Gaming: Professional-Grade Gear Meets Unbeatable Value
Published on 03/19/2026 at 23:48, 4 hours 56 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C daily buy back notice
Published on 03/19/2026 at 22:55, 5 hours 49 minutes ago

Baristas behind millions of cups of coffee compete globally
Published on 03/19/2026 at 22:48, 5 hours 56 minutes ago

EQS-Adhoc: Forecast for the 2026 financial year
Published on 03/19/2026 at 19:30, 9 hours 14 minutes ago

EEII AG: Publication of Listing Prospectus

View all EQS

Published on 03/19/2026 at 18:00, 10 hours 45 minutes ago

Filing of the 2025 Universal Registration Document
Published on 03/19/2026 at 18:00, 10 hours 45 minutes ago

Mise à disposition du Document d’Enregistrement Universel 2025
Published on 03/19/2026 at 15:00, 13 hours 45 minutes ago

Statement Accor
Published on 03/19/2026 at 15:00, 13 hours 45 minutes ago

Communication Accor
Published on 03/19/2026 at 08:45, 20 hours ago

Deezer et Sonos renouvellent et étendent leur partenariat stratégique

View all LES ECHOS COMFI WIRE

News